(Q41673381)

6 October 2017

1 reference

title

New antipsychotic medications: strategies for evaluation and selected findings (English)

1 reference

6 October 2017

N R Schooler

1

1 reference

6 October 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

6 October 2017

published in

Schizophrenia Research

1 reference

6 October 2017

volume

27

1 reference

6 October 2017

issue

2-3

1 reference

6 October 2017

page(s)

249-259

1 reference

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Risperidone in Elderly Schizophrenic Patients: An Open-Label Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Treatment-resistant schizophrenia: clinical experience with new antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

The rationale and ethics of medication-free research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Trial of Maintenance Therapy in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Clozapine in Older Patients With Psychosis and Behavioral Disruption

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Maintenance Medication for Schizophrenia: Strategies for Dose Reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

Informed consent and bias in samples of schizophrenic subjects at risk for drug withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2897%2900089-3

7 January 2021

10.1016/S0920-9964(97)00089-3

Identifiers

DOI

1 reference

6 October 2017

1 reference